{"id":"https://openalex.org/W2603219465","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.5066","title":"Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer.","display_name":"Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer.","publication_year":2013,"publication_date":"2013-05-20","ids":{"openalex":"https://openalex.org/W2603219465","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.5066","mag":"2603219465"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2013.31.15_suppl.5066","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.5066","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.5066","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5081246052","display_name":"Mark T. Fleming","orcid":"https://orcid.org/0000-0001-9120-9587","observed_orcids":["https://orcid.org/0000-0001-9120-9587"]},"institutions":[{"id":"https://openalex.org/I4210088931","display_name":"Virginia Oncology Associates","ror":"https://ror.org/009yyqs39","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210088931"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark T. Fleming","raw_affiliation_strings":["Virginia Oncology Associates, Norfolk, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Oncology Associates, Norfolk, VA","institution_ids":["https://openalex.org/I4210088931"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002358672","display_name":"Dana E. Rathkopf","orcid":"https://orcid.org/0000-0002-4503-7582","observed_orcids":["https://orcid.org/0000-0002-4503-7582"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dana E. Rathkopf","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058462058","display_name":"Jackie Gibbons","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267655","display_name":"Medivation, Inc. (United States)","ror":"https://ror.org/03rkn0606","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267655"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jackie Gibbons","raw_affiliation_strings":["Medivation, Inc., San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medivation, Inc., San Francisco, CA","institution_ids":["https://openalex.org/I4405267655"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037339262","display_name":"Amy Peterson","orcid":"https://orcid.org/0000-0001-8273-1365","observed_orcids":["https://orcid.org/0000-0001-8273-1365"]},"institutions":[{"id":"https://openalex.org/I4405267655","display_name":"Medivation, Inc. (United States)","ror":"https://ror.org/03rkn0606","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267655"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy C. Peterson","raw_affiliation_strings":["Medivation, Inc., San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medivation, Inc., San Francisco, CA","institution_ids":["https://openalex.org/I4405267655"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089364285","display_name":"Alison L. Hannah","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267655","display_name":"Medivation, Inc. (United States)","ror":"https://ror.org/03rkn0606","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267655"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alison Hannah","raw_affiliation_strings":["Medivation, Inc., San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medivation, Inc., San Francisco, CA","institution_ids":["https://openalex.org/I4405267655"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016173669","display_name":"David Forer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267655","display_name":"Medivation, Inc. (United States)","ror":"https://ror.org/03rkn0606","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267655"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Forer","raw_affiliation_strings":["Medivation, Inc., San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medivation, Inc., San Francisco, CA","institution_ids":["https://openalex.org/I4405267655"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072850546","display_name":"Howard I. Scher","orcid":"https://orcid.org/0000-0002-6791-9324","observed_orcids":["https://orcid.org/0000-0002-6791-9324"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard I. Scher","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5017288060","display_name":"Michael J. Morris","orcid":"https://orcid.org/0000-0002-9454-0096","observed_orcids":["https://orcid.org/0000-0002-9454-0096"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Morris","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"15_suppl","first_page":"5066","last_page":"5066"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/enzalutamide","display_name":"enzalutamide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":1.0},{"id":"https://openalex.org/keywords/metastatic-castration-resistant-prostate-cancer","display_name":"metastatic castration-resistant prostate cancer","score":0.9070000052452087},{"id":"https://openalex.org/keywords/androgen-receptor-antagonists","display_name":"androgen receptor antagonists","score":0.8669999837875366},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.527999997138977},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9559999704360962},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.7940000295639038},{"id":"https://openalex.org/keywords/cyp3a4","display_name":"CYP3A4","score":0.8759999871253967},{"id":"https://openalex.org/keywords/androgen-deprivation-therapy","display_name":"androgen deprivation therapy","score":0.9039999842643738},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.7170000076293945},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.5899999737739563},{"id":"https://openalex.org/keywords/androgen-receptor-signaling","display_name":"androgen receptor signaling","score":0.39800000190734863},{"id":"https://openalex.org/keywords/peripheral-neuropathy","display_name":"peripheral neuropathy","score":0.5320000052452087},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8149999976158142},{"id":"https://openalex.org/keywords/dysgeusia","display_name":"dysgeusia","score":0.734000027179718}],"concepts":[{"id":"https://openalex.org/C2776551883","wikidata":"https://www.wikidata.org/wiki/Q1996756","display_name":"Enzalutamide","level":5,"score":0.9757342338562012},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.8841441869735718},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8396746516227722},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.7608959078788757},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.6533312797546387},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5206707715988159},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4937661588191986},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.47593358159065247},{"id":"https://openalex.org/C2777899217","wikidata":"https://www.wikidata.org/wiki/Q4759439","display_name":"Androgen deprivation therapy","level":4,"score":0.4252830743789673},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4015212059020996},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.35911500453948975},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.32497555017471313}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2013.31.15_suppl.5066","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.5066","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.5066","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2474221052","https://openalex.org/W2256020981","https://openalex.org/W2890009698","https://openalex.org/W4379283143","https://openalex.org/W3192742601","https://openalex.org/W2590294003","https://openalex.org/W4406185689","https://openalex.org/W2891380196","https://openalex.org/W2595859672","https://openalex.org/W2797537614"],"abstract_inverted_index":{"5066":[0],"Background:":[1],"Enzalutamide":[2],"(ENZA)":[3],"is":[4,63],"a":[5,47,57,70,322],"novel":[6],"androgen":[7,104],"receptor":[8],"(AR)":[9],"inhibitor":[10],"that":[11],"prolongs":[12,30],"survival":[13,31],"in":[14,32,59,99,244,253,287],"men":[15,100],"with":[16,97,101,118,289],"metastatic":[17],"castration-resistant":[18],"prostate":[19],"cancer":[20],"(mCRPC)":[21],"who":[22],"had":[23,218],"received":[24,108],"prior":[25],"docetaxel":[26],"(DOC).":[27],"DOC":[28,60,95,109,130,146,153,171,281,286,292,319,327],"also":[29,35],"mCRPC":[33,102,309],"and":[34,62,78,91,144,198,200,268,295,298],"appears":[36],"to":[37,74,148,164,315],"have":[38,321],"anti-tumor":[39],"effects":[40],"mediated":[41],"through":[42],"the":[43,52,76,89,128],"androgen-receptor":[44],"axis,":[45],"providing":[46],"compelling":[48],"rationale":[49],"for":[50,137,174,285],"combining":[51],"two":[53],"agents.":[54],"CYP3A4":[55],"plays":[56],"role":[58],"clearance":[61],"induced":[64],"by":[65,112],"ENZA.":[66,156],"We":[67],"therefore":[68],"conducted":[69],"phase":[71],"I":[72],"study":[73,86],"explore":[75],"PK":[77,133,154,175,197,276,294],"safety":[79,90,202],"profiles":[80],"of":[81,94,152,160,170,189,192,318],"this":[82],"combination.":[83],"Methods:":[84],"This":[85],"(NCT01565928)":[87],"evaluated":[88],"pharmacokinetics":[92],"(PK)":[93],"co-administered":[96],"ENZA":[98,120,290,311],"on":[103,326],"deprivation":[105],"therapy.":[106],"Pts":[107],"(75":[110],"mg/m2)":[111],"1-h":[113],"infusion":[114],"every":[115],"3":[116],"weeks":[117],"corticosteroids.":[119],"(160":[121],"mg/d)":[122],"was":[123,172,212,238,242],"started":[124],"24":[125,138],"h":[126,139],"after":[127,140],"first":[129],"infusion.":[131],"Plasma":[132],"samples":[134],"were":[135,180,204,273],"collected":[136],"Cycle":[141,302],"(C)":[142],"1":[143,222],"C2":[145,201],"infusions":[147],"enable":[149],"within-subject":[150],"comparisons":[151],"\u00b1":[155],"A":[157],"sample":[158],"size":[159],"18":[161],"pts":[162,179,246,255],"able":[163],"receive":[165,185],"\u2265":[166],"2":[167,186,303],"full":[168,187],"doses":[169,188],"specified":[173],"analyses.":[176],"Results:":[177],"Twenty-two":[178],"enrolled,":[181],"4":[182],"did":[183],"not":[184,313],"DOC.":[190],"As":[191],"21":[193],"Sept":[194],"2012,":[195],"preliminary":[196],"C1":[199],"data":[203,277,300],"available":[205],"from":[206],"15":[207],"pts.":[208],"The":[209],"median":[210,236],"age":[211],"65":[213],"(range":[214],"46-80":[215],"yrs);":[216],"11":[217],"ECOG":[219],"performance":[220],"status":[221],"(vs":[223],"0).":[224],"Prior":[225],"primary":[226],"therapy":[227],"included":[228,256],"surgery":[229],"(n=2),":[230],"radiation":[231],"(n=4)":[232],"or":[233,320],"both":[234],"(n=5);":[235],"PSA":[237],"44.7ng/mL":[239],"(1.9-585).":[240],"ANC<1000/mm3":[241],"reported":[243],"14":[245],"(1":[247],"febrile":[248],"neutropenia),":[249],"other":[250],"adverse":[251],"events":[252],"\u22654":[254],"fatigue":[257],"(11),":[258],"dyspnea":[259],"(6),":[260],"alopecia":[261],"(5),":[262,265],"peripheral":[263],"neuropathy":[264],"anemia":[266],"(4)":[267],"dysgueusia":[269],"(4).":[270],"No":[271],"seizures":[272],"reported.":[274],"Preliminary":[275],"(n=15)":[278],"show":[279],"similar":[280],"exposure":[282],"(within":[283],"20%)":[284],"combination":[288],"vs.":[291],"alone.Final":[293],"updated":[296],"tolerability":[297,317],"efficacy":[299],"beyond":[301],"will":[304],"be":[305],"presented.":[306],"Conclusions:":[307],"In":[308],"pts,":[310],"does":[312],"appear":[314],"affect":[316],"clinically":[323],"meaningful":[324],"impact":[325],"PK.":[328],"Clinical":[329],"trial":[330],"information:":[331],"NCT01565928.":[332]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-04-07T00:00:00"}